Develop P&R strategies supporting OD launch in ex-US markets

Client Challenge

Assess the commercial opportunity of an innovative therapy in major markets

Following positive phase 2a results, the client wished to understand the commercial opportunity for a novel mRNA-based therapy for heart failure in the US, UK, Germany, and China markets in 2032 in order to guide future investment decisions

P4A Solution

P4A assessed the current and future competitive landscape, recognition of the product, and possible coverage pathways in a hospital setting

  • Research with hospital payers and KOLs to validate landscape, access, and pricing hypotheses

We identified value potential, pricing and access considerations, and evidence gaps


The Successful Outcome

  • Understood the current and future P&R, expected market access and coverage pathways, evidence gaps, and competitive landscape for the product in each market
  • Identified evidence and market shaping mitigation measures to further optimise the P&R / commercial potential of the product
P4A were flexible and patient with us as the project was delayed. We embrace deadlines and completed the project in half the time, which showed P4A’s commitment to support & partner with us
Global Pricing & Reimbursement Director